Past transaction from cutting edge academic research to successful IPO on the London Stock Exchange:

pushing the boundaries of science and changing the world for the better

We help finance clinical research and development in the following indications

Thrombosis and stroke prevention

Beginning of the phase III.
Immuno-modulatory platform.
Portfolio of PDI inhibitors.

Mutliple Sclerosis

Best-in-class single clinical phase III data. At least at parity with Roche’s Ocrevus, the current gold standard, but with different mechanism of action. Ideal combo

Amyotrophic Lateral Sclerosis

Best-in-class single clinical Phase III data. Superior to Amylyx, Ederavone. Waiting for conditional approval by Health Canada and FDA

HPV / HIV / Dengue Fever / West Nile / Malaria

Next generation vaccine & immunotherapy platform from Pasteur
Multiple Phase 1/2 with 100% positive responses

Complex Polyp Surgery / GI

Next generation upper and lower GI diagnostic & surgical platform. Natural takeover by big MedTech interested to expand and improve their GI platform (Medtronic, J&J, Olympus, Boston S)

Sickle Cell Anemia

Phase IIb with group of university hospitals
Inherited disorder modi-cation of red blood cells
5-10% prevalence in MENA region. 350K new patients/yr
Alternative to $2m stem cell treatment

Stroke Detection

Immediate and on-location blood test analysis, reducing critical triage time at hospital. Natural takeover by major diagnostic platform (Abbott, Roche)

Emerging evidence of potential brake through in anti-cancer treats

traitement-tumeur-au-cerveau-2-icon

Brain tumor

Beginning of the phase III. Venous thromboembolism (VTE) prevention in cancer (Phase III). Reduce cancer metastasis
lung-cancer-icon

Lung cancer

Beginning of the phase III. Venous thromboembolism (VTE) prevention in cancer (Phase III). Reduce cancer metastasis
que-savez-vous-sur-les-fibromes-wat-weet-u-over-fibromen720x320-e424b225

Ovarian cancer

Beginning of the phase III. Venous thromboembolism (VTE) prevention in cancer (Phase III). Reduce cancer metastasis
pancreatic-cancer-icon

Pancreatic cancer

Beginning of the phase III. Venous thromboembolism (VTE) prevention in cancer (Phase III). Reduce cancer metastasis


PHILANTHROPY

SUPPORTED MUSICIANS

Nelson Goerner
Goldmund Quartett
Valeriy Sokolov
Dimitry Udovichenko
Igor Levit
Piotr Anderszewski
Kit Armstrong

Contacts

pf-scaledsharp-square-desatured

Philippe Froehlicher

Managing Partner

+30 years of experience in portfolio management and capital markets. +10 years of experience in private equity.

In 2009, he co-founded FGP Capital. His responsibilities include the strategic development of the firm. Philippe oversees asset allocation and investment decisions. Prior to 2009, Philippe ran discretionary global mandates for HNWI at Pictet & Cie since 1998.

Philippe has studied with world famous professors in corporate strategy, including Michael Porter (Harvard) and Klaus Schwab (World Economic Forum). He holds a Master in Business Administration & Economics from the University of Geneva, where he specialized in finance and corporate strategy.

Richard-square-desatured

Richard Ormond

Managing Partner

+35 years of investment experience in fund, portfolio and client management. +10 years of experience in private equity

His expertise has expanded from traditional investments to private equity and debt investments in growth capital for life science, technology and consumer companies.

Prior to joining the Group in 2012, Richard spent 22 years as client and fund manager (Small Caps and Emerging Markets) with Pictet & Cie. Richard holds a Master in Business & Management and completed his studies with a postgraduate Diploma in Economics & Finance from the University of Geneva.

For wealth management, financial advisory, please contact

Mr. Rene Grand

at BOCCARD FINANCE SA, Geneva, Switzerland, a FINMA regulated entity:
+ 41 22 908 01 88 / rene.grand@boccardfinance.ch

logo-transp

© 2025 FGP CAPITAL
Geneva, Switzerland

Legal Notice

7, Rue des Alpes
1201 Genève
Switzerland
info@fgpcapital.com
+41 (0) 22 753 53 53